1 / 34

STD and HIV Emerging Issues

STD and HIV Emerging Issues. Gail Bolan MD Chief, STD Control Branch CA Department of Health Services Assistant Clinical Professor Department of Medicine, UCSF. Overview of Complications of Sexually Transmitted Diseases. Fetal Wastage* Low Birthweight* Congenital Infection*.

denis
Download Presentation

STD and HIV Emerging Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. STD and HIV Emerging Issues Gail Bolan MD Chief, STD Control Branch CA Department of Health Services Assistant Clinical Professor Department of Medicine, UCSF

  2. Overview of Complications ofSexually Transmitted Diseases Fetal Wastage* Low Birthweight* Congenital Infection* Upper Tract Infection Systemic Infection Infertility Ectopic Pregnancy* Chronic Pelvic Pain STDs Cervical Cancer* HIV Infection* * Potentially Fatal

  3. STD MorbidityCalifornia and United States 2002

  4. Public Health Functions STD Prevention Activities Monitor health status Surveillance Diagnosis and investigate health problems Screening and DIS follow-up Inform and empower people about health issues Health Education Mobilize community partnerships and action Community mobilization Develop policies and plans that support efforts Advocacy, strategic planning and guidelines 10 Core Public Health Functions and STD Activities

  5. Public Health Functions STD Prevention Activities Enforce laws and regulations Legislation and Regulations Link people to services and ensure provision of care when unavailable Access to and provision of quality care Ensure competent workforce Staffing and staff development Evaluate the effectiveness, accessibility, and quality of services Evaluation Research new insights and innovative solutions Research 10 Core Public Health Functions and STD Activities

  6. STD Prevention and Control Strategies • Education and counseling (primary prevention) • Project Respect • Identification of asymptomatic persons (secondary prevention) • Screening • HEDIS • Identification of symptomatic persons (secondary prevention) • Effective diagnosis and treatment (secondary prevention) • Test Performance Characteristics • Empiric Treatment • Partner Management (primary and secondary prevention) • Vaccination ( ideally primary prevention)

  7. Syphilis — Reported cases: US, 1941–2001

  8. Primary and secondary syphilis - County rates, 1998

  9. Syphilis: Overview of Stages 30% 5-50 years 1º 2º Latent 3º Early Syphilis Late Syphilis

  10. Epidemiologic Vulnerability of Syphilis • No animal reservoir • Long incubation period • Limited infectiousness • Low cost and widely available diagnostic tests • Single dose therapy • No antimicrobial resistance

  11. Syphilis Elimination:Public Health Importance • Important, measurable health outcomes • Substantial cost savings • Annual cost savings of ~1 billion • Supports multiple public health goals • Reduction of racial disparities • Infectious disease control, including HIV prevention • Bio-terrorism preparedness • Reproductive health and infant health • Identifies opportunities to improve public health infrastructure • Focus for critical collaboration between communities & health departments • Addresses unfinished history & broken trust

  12. Primary & Secondary Syphilis Cases by Gender, California, 1996–2002 Rate per 100,000 ALL MALE known MSM FEMALE 5/03 Provisional Data - CA DHS STD Control Branch

  13. Risk Characteristics of MSM P&S Syphilis Cases, California 1999-2002 1 Percentage excludes unknown 5/03 Provisional Data - CA DHS STD Control Branch

  14. Gonorrhea Rates by Gender, California, 1993–2002 Rate per 100,000 Source: California Department of Health Services, STD Control Branch Provisional Data 05/16/2003

  15. Gonococcal Isolate Surveillance Project (GISP), Percent of NeisseriaGonorrhoeae Isolates with Decreased Susceptibility or Resistance to Ciprofloxacin, California Sites, 1991–2002 Note: Resistant isolates have MICs ≥ 1 μg ciprofloxacin/mL. Isolates with decreased susceptibility have MICs of 0.125 – 0.5 μg ciprofloxacin/mL. STD Clinic Sites: Long Beach, Orange, San Diego, San Francisco Source: California Department of Health Services, STD Control Branch

  16. Gonococcal Isolate Surveillance Project (GISP) - Location of participating clinics and regional laboratories: United States, 1998

  17. Gonorrhea TreatmentGenital & Rectal Infections in Adults Recommended regimens: • Cefixime 400 mg PO x 1 or • Ceftriaxone 125 mg IM x 1 or • Ciprofloxacin 500 mg PO x 1 or • Ofloxacin 400 mg PO x 1 or • Levofloxacin 250 mg PO x 1 PLUSif chlamydia is not ruled out: • Azithromycin 1 g PO x 1 or • Doxycycline 100 mg PO BID x 7 d

  18. Why Chlamydia & Why Now? • Most common communicable disease reported disease in California • Over 100,000 reported cases in 2001 • Over 75% of cases are seen in the private sector • Significant health consequences • Most common cause of preventable infertility • Facilitates sexual transmission of HIV • New technology = new opportunity • Urine tests & single dose treatment = easier to reach, treat & cure at-risk populations • HEDIS increases private sector interest • Potential public/private partnership

  19. Chlamydia Action Coalition A State-Wide Public/Private Partnership funded by the California HealthCare Foundation www.ucsf.edu/castd

  20. Chlamydia Screening HEDIS Measure • The Measure:the percentage of Medicaid and commercially enrolled women 15 through 25 who were identified as sexually active, who were continuously enrolled during the reporting year, and who have at least one test for chlamydia during the reporting year. Number tested Numberof sexually active * * Denominator may exclude plan employees to protect confidentiality Source: CDC, NCHSTP, DSTDP

  21. Chlamydia HEDIS Data Warehouse • Centralized Data Warehouse with Electronic Transmission of Chlamydia Screening Data • Collection of HEDIS numerator data • Prevalence Monitoring • Coordinate with ELR of communicable diseases

  22. HIPAA Basics • What is HIPAA? • Health Insurance Portability and Accountability Act • Provides the first national standards for protecting the privacy of health information • HIPAA Privacy Rule regulates how certain entities, called covered entities, use and disclose certain protected health information (PHI)

  23. Who is Covered? • Three types of covered entities • health plans, (e.g., Medicaid, Medicare, and the Veterans Health Administration) • health-care clearinghouses, (billing service, repricing company, or community health information system) • health-care providers who transmit health information in electronic form in connection with certain transactions (e.g., physicians, hospitals, and clinics)

  24. Impact on Public Health • Public health uses PHI to identify, monitor, and respond to disease, death, and disability among populations • Privacy Rule expressly permits PHI to be shared by covered entities for specified public health purposes • Public health authority may also be a covered entity in some cases

  25. Permitted PHI Disclosures Without Authorization • Where required by law • PHI can be disclosed to public health authorities and their authorized agents for public health purposes • Health research • Abuse, neglect, or domestic violence • Law enforcement • Judicial and administrative proceedings. • Cadaveric organ, eye, or tissue donation purposes • For oversight activities authorized by law • Worker's compensation

  26. Included Public Health Activities • reporting of disease or injury • reporting vital events (e.g., births or deaths) • conducting public health surveillance, investigations, or interventions • reporting child abuse and neglect • monitoring adverse outcomes related to food (including dietary supplements), drugs, biological products, and medical devices

  27. Requirements for Covered Entities • Accounting for Public Health Disclosures • Covered entity must be able to provide a patient an accounting of disclosure even for disclosures permitted or required by law • Notice of Privacy Practices • individuals have the right to adequate notice of the uses and disclosures of PHI that may be made by the covered entity, as well as their rights and the covered entity's legal obligations • Minimum Necessary Standard • directs covered entities to limit the amount of information disclosed to the minimum necessary to achieve the specified goal

  28. Rapid HIV Testing A key strategy of the Advancing HIV Prevention Initiative is to use rapid HIV tests to expand HIV testing outside clinical settings.

  29. Reactive Control Positive HIV-1 Positive Negative Read results

  30. STD Resources for Clinicians California STD/HIV Prevention Training Center www.stdhivtraining.org CDC Treatment Guidelines www.cdc.gov/std/treatment California Chlamydia Action Coalition www.ucsf.edu/castd CA STD Control Branch www.dhs.ca.gov/ps/dcdc/STD/stdindex.htm

More Related